Skip to main content
. 2023 Apr 3;11(1):479–494. doi: 10.1016/j.gendis.2023.02.035

Figure 5.

Fig. 5

CYY292 suppresses the stemness of GBM cells. (A, C) Immunoblot analyses of Nanog and Sox 2 levels in U87MG and LN229 cells treated with vehicle or CYY292 at 0.3, 0.5, and 1 μM for 24 h (n = 3). (B, D) qPCR analysis of Nanog, Sox2, and Oct 4 levels in cells treated as described in (A, C) (n = 3). (E, G) U87MG and LN229 cells were seeded in six-well plates and treated with 0.5 or 1 μM CYY292 or vehicle for colony formation assay. (F, H) Quantification of the U87MG cells and LN229 as shown in (E, G). (I, K) Immunoblot analyses of pIκBα/IκBα, p-p65/p65, and p-p38/p38 levels in U87MG and LN229 cells treated with vehicle or CYY292 at 0.3, 0.5, and 1 μM for 24 h. β-Actin was used as a protein-loading protein. (J, L) qPCR analysis of the levels of chemokine cytokines (IL1β, IL6, IL8, IL11) and chemokines (CCl2, CCl5) in cells treated as described in (A, C) (n = 3). All data are presented as means ± SD (n = 3 independent experiments). ∗P < 0.05, ∗∗P < 0.01, #P > 0.05. Differences are tested using one-way analysis of variance (ANOVA) with Tukey's post hoc test.